WO1999043815A3 - Anticorps monoclonaux humains capables de reconnaitre de maniere oligospecifique les principaux gangliosides associes aux tumeurs, et leurs procedes d'utilisation - Google Patents

Anticorps monoclonaux humains capables de reconnaitre de maniere oligospecifique les principaux gangliosides associes aux tumeurs, et leurs procedes d'utilisation Download PDF

Info

Publication number
WO1999043815A3
WO1999043815A3 PCT/CA1999/000178 CA9900178W WO9943815A3 WO 1999043815 A3 WO1999043815 A3 WO 1999043815A3 CA 9900178 W CA9900178 W CA 9900178W WO 9943815 A3 WO9943815 A3 WO 9943815A3
Authority
WO
WIPO (PCT)
Prior art keywords
human monoclonal
recognizing
oligospecifically
methods
monoclonal antibodies
Prior art date
Application number
PCT/CA1999/000178
Other languages
English (en)
Other versions
WO1999043815A2 (fr
Inventor
Michael E Mcknight
Mark C Glassy
Original Assignee
Novopharm Biotech Inc
Michael E Mcknight
Mark C Glassy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novopharm Biotech Inc, Michael E Mcknight, Mark C Glassy filed Critical Novopharm Biotech Inc
Priority to AU32427/99A priority Critical patent/AU3242799A/en
Priority to EP99936093A priority patent/EP1056861A2/fr
Priority to CA002322003A priority patent/CA2322003A1/fr
Publication of WO1999043815A2 publication Critical patent/WO1999043815A2/fr
Publication of WO1999043815A3 publication Critical patent/WO1999043815A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

On a isolé, séquencé et caractérisé un anticorps monoclonal capable de reconnaître les principaux gangliosides associés aux tumeurs. L'anticorps monoclonal humain et les Fab qu'il contient sont utiles pour la détection d'antigènes associés aux tumeurs, pour le diagnostic de cellules cancéreuses exprimant les antigènes et pour le traitement thérapeutique des cancers.
PCT/CA1999/000178 1998-02-27 1999-02-26 Anticorps monoclonaux humains capables de reconnaitre de maniere oligospecifique les principaux gangliosides associes aux tumeurs, et leurs procedes d'utilisation WO1999043815A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU32427/99A AU3242799A (en) 1998-02-27 1999-02-26 Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof
EP99936093A EP1056861A2 (fr) 1998-02-27 1999-02-26 Anticorps monoclonaux humains capables de reconnaitre de maniere oligospecifique les principaux gangliosides associes aux tumeurs, et leurs procedes d'utilisation
CA002322003A CA2322003A1 (fr) 1998-02-27 1999-02-26 Anticorps monoclonaux humains capables de reconnaitre de maniere oligospecifique les principaux gangliosides associes aux tumeurs, et leurs procedes d'utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7620098P 1998-02-27 1998-02-27
US60/076,200 1998-02-27

Publications (2)

Publication Number Publication Date
WO1999043815A2 WO1999043815A2 (fr) 1999-09-02
WO1999043815A3 true WO1999043815A3 (fr) 1999-11-25

Family

ID=22130549

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000178 WO1999043815A2 (fr) 1998-02-27 1999-02-26 Anticorps monoclonaux humains capables de reconnaitre de maniere oligospecifique les principaux gangliosides associes aux tumeurs, et leurs procedes d'utilisation

Country Status (4)

Country Link
EP (1) EP1056861A2 (fr)
AU (1) AU3242799A (fr)
CA (1) CA2322003A1 (fr)
WO (1) WO1999043815A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002078739A1 (fr) * 2001-03-29 2002-10-10 Kyowa Hakko Kogyo Co., Ltd. Medicaments contenant un anticorps genetiquement modifie dirige contre un ganglioside gd3
CA2498778A1 (fr) 2002-09-11 2004-03-25 Shantha West, Inc. Anticorps reconnaissant les cellules hyperproliferatives et procedes de production et d'utilisation de ces anticorps

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0480440A1 (fr) * 1990-10-11 1992-04-15 Roche Diagnostics GmbH Anticorps monoclonal contre le mélanome
EP0492409A1 (fr) * 1990-12-18 1992-07-01 Ishihara Sangyo Kaisha, Ltd. Anticorps monoclonal humain
WO1994019457A1 (fr) * 1993-02-26 1994-09-01 The Regents Of The University Of California Lignee de cellules b-lymphoblastoides humaines secretant un anticorps anti ganglioside

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0480440A1 (fr) * 1990-10-11 1992-04-15 Roche Diagnostics GmbH Anticorps monoclonal contre le mélanome
EP0492409A1 (fr) * 1990-12-18 1992-07-01 Ishihara Sangyo Kaisha, Ltd. Anticorps monoclonal humain
WO1994019457A1 (fr) * 1993-02-26 1994-09-01 The Regents Of The University Of California Lignee de cellules b-lymphoblastoides humaines secretant un anticorps anti ganglioside

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
H. YAMAGUCHI ET AL.: "Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A., vol. 87, no. 9, May 1990 (1990-05-01), Washington, DC, USA, pages 3333 - 3337, XP002116959 *
K. FURUKAWA ET AL.: "Two human monoclonal antibodies reacting with the major gangliosides of human melanomas and comparison with corresponding mouse monoclonal antibodies.", CANCER RESEARCH, vol. 49, no. 1, 1 January 1989 (1989-01-01), Baltimore, MD, USA, pages 191 - 196, XP000608629 *
M. ALFONSO ET AL.: "Generation of human monoclonal antibodies against ganglioside antigens and their applications in the diagnosis and therapy of cancer.", ACTA ONCOLOGICA, vol. 35, no. 3, 1996, Stockholm, Sweden, pages 287 - 295, XP002116960 *
S. MUKERJEE ET AL.: "Characterization of human IgG1 monoclonal antibody against gangliosides expressed on tumor cells.", HYBRIDOMA, vol. 17, no. 2, April 1998 (1998-04-01), New York, NY, USA, pages 133 - 142, XP002116961 *
Z. ABDEL-WAHAB ET AL.: "Cell surface reactive human monoclonal antibody directed to human melanoma-associated gangliosides.", MELANOMA RESEARCH, vol. 3, no. 6, December 1993 (1993-12-01), Oxford, GB, pages 415 - 423, XP000608631 *

Also Published As

Publication number Publication date
CA2322003A1 (fr) 1999-09-02
AU3242799A (en) 1999-09-15
EP1056861A2 (fr) 2000-12-06
WO1999043815A2 (fr) 1999-09-02

Similar Documents

Publication Publication Date Title
HUP0200537A2 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
WO2004001381A3 (fr) Cible de surface cellulaire raag10 et famille d'anticorps reconnaissant cette cible
MD1374G2 (ro) Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică
WO2004032857A8 (fr) Therapie fondee sur les anticorps
AU6266899A (en) Methods for producing human tumor antigen specific antibodies
DE69734109D1 (de) Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung
WO2000073801A3 (fr) Antigenes associes au cancer du sein, de la prostate et de l'estomac et leur utilisation
WO2002006317A3 (fr) Compositions et procedes utilises dans la therapie et le diagnostic du cancer des ovaires
AU2190997A (en) Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation
ES2176574T3 (es) Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral.
IE890720L (en) Improvements relating to antigens
WO2000036107A3 (fr) Compositions et procedes destines a la therapie et au diagnostic du cancer de l"ovaire
WO2002016413A3 (fr) Vaccins
TR200001253T2 (tr) Tümöre özel antijenler
IL126803A0 (en) Method and composition for reconforming multi-epitopic antigens to initiate an immune response
WO2004043239A3 (fr) Antigene pipa et anticorps de liaison a celui-ci
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
WO2002078516A3 (fr) Compositions et methodes de traitement et de diagnostic de cancers
EP0352722A3 (fr) Procédés de liaison d'antigène d'adènocarcinome et réactifs
AU2829889A (en) Sf-25 colon adenocarcinoma antigen, and antibodies which recognize this antigen
WO2000032635A3 (fr) Anticorps monoclonaux humains specifiques de tumeurs et leur technique d'utilisation
WO1999043815A3 (fr) Anticorps monoclonaux humains capables de reconnaitre de maniere oligospecifique les principaux gangliosides associes aux tumeurs, et leurs procedes d'utilisation
IL138021A0 (en) High affinity humanized anti-tag-72 monoclonal antibodies
WO2001036485A3 (fr) Anticorps et fragment fv reconnaissant l'antigene ior c2
AU2070688A (en) Antigen recognized by mca 16-88

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 32427/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2322003

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2322003

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09648624

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1999936093

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999936093

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999936093

Country of ref document: EP